IMS HEALTH |
|
|---|---|
| Sales Through Retail Pharmacies | |
| (Twelve months to May 2008) | |
| NORTH AMERICA $223.3billion | up 2% |
| United States $206.5billion | up 1% |
| Canada $16.7billion | up 6% |
| EUROPE (Top 5) $114.3billion | up 4% |
| Germany $34.4billion | up 7% |
| France $30.8billion | up 4% |
| United Kingdom $17.1billion | 0% |
| Italy $16.9billion | 0% |
| Spain $14.8billion | up 7% |
| JAPAN (including hospitals) $63.2billion | up 5% |
| LATIN AMERICA (Top 3) $23.2billion | up 9% |
| Brazil $11.6billion | up 10% |
| Mexico $8.7billion | up 6% |
| Argentina $2.8billion | up 21% |
| AUSTRALIA/NEW ZEALAND $7.8billion | up 13% |
The top 5 therapy classes at ATC3 level in the 12 months to May 2008 were:
1. C10A - Cholesterol & Triglyceride regulators
2. A2B - Antiulcerants
3. N6A - Antidepressants & mood stabilisers
4. N5A - Antipsychotics
5. N3A - Anti-epileptics
The top 5 products in the 12 months to May 2008 were:
1. Lipitor
2. Nexium
3. Plavix
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to May 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. Novartis
4. Astrazeneca
5. Merck & Co
